Table 1.
Maternal characteristics and breastmilk Ig levels.
| Groups | Month of Lactation | Maternal Age (years) | Maternal BMI | Disease Duration (years) | Concomitant Medication |
SIgA µg/mL |
SIgM µg/mL |
|---|---|---|---|---|---|---|---|
| non-IBD controls for CD (n = 24) |
3 ± 2 | 35 ± 6 | 25 ± 6 | N/A | N/A | 292 ± 153 | 51 ± 33 |
| CD—vdz (n = 15) |
4 ± 4 | 33 ± 3 | 25 ± 4 | 9 ± 6 | anti-TNF, ustekinumab, 6-MP, Prednisone |
322 ± 207 | 46 ± 24 |
| CD + vdz (n = 9) |
3 ± 2 | 32 ± 3 | 25 ± 4 | 11 ± 6 | 5-ASA, 6-MP, tofacitinib |
256 ± 80 | 69 ± 32 |
| non-IBD controls for UC (n = 21) |
6 ± 5 | 33 ± 5 | 25 ± 4 | N/A | N/A | 312 ± 143 | 61 ± 41 |
| UC—vdz (n = 7) |
5 ± 2 | 35 ± 5 | 25 ± 6 | 8 ± 5 | anti-TNF, ustekinumab, 6-MP |
212 ± 149 | 58 ± 26 |
| UC + vdz (n = 10) |
6 ± 5 | 34 ± 7 | 26 ± 5 | 14 ± 4 | 5-ASA | 283 ± 87 | 65 ± 34 |